Logo

EVR

Evercore Inc.

EVR

Evercore Inc. • NYSE
$320.07 ▲ 1.14% (+3.61)
Market Cap $12.35 B
52w High $364.42
52w Low $148.63
Dividend Yield 4.12%
P/E 25.44
Volume 177.25K
Outstanding Shares 38.60M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.046B ▲ $821.596M ▲ $144.583M ▲ 13.823% ▲ $3.73 ▲ $217.445M ▲
Q2-2025 $838.04M ▲ $682.626M ▲ $97.201M ▼ 11.599% ▼ $2.51 ▼ $152.249M ▲
Q1-2025 $699.022M ▼ $582.766M ▼ $146.184M ▲ 20.913% ▲ $3.78 ▲ $114.628M ▼
Q4-2024 $979.525M ▲ $761.797M ▲ $140.435M ▲ 14.337% ▲ $3.67 ▲ $212.733M ▲
Q3-2024 $738.42M $611.157M $78.393M 10.616% $2.05 $122.401M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.705B ▼ $4.422B ▲ $2.337B ▲ $1.809B ▲
Q2-2025 $1.735B ▲ $3.69B ▲ $1.771B ▲ $1.655B ▲
Q1-2025 $1.364B ▲ $3.271B ▼ $1.519B ▼ $1.507B ▼
Q4-2024 $939.705M ▼ $4.174B ▲ $2.232B ▲ $1.708B ▲
Q3-2024 $1.215B $3.568B $1.788B $1.557B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $157.494M ▲ $560.913M ▲ $-453.838M ▼ $132.592M ▲ $234.342M ▲ $541.479M ▲
Q2-2025 $106.939M ▼ $437.737M ▲ $-314.153M ▼ $-80.948M ▲ $64.509M ▲ $411.691M ▲
Q1-2025 $153.79M ▲ $-549.653M ▼ $679.761M ▲ $-460.857M ▼ $-319.367M ▼ $-569.313M ▼
Q4-2024 $140.435M ▲ $686.384M ▲ $-246.562M ▼ $-77.901M ▲ $340.078M ▲ $673.052M ▲
Q3-2024 $78.393M $234.5M $-204.732M $-139.664M $-98.429M $226.649M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Investment Banking and Equities
Investment Banking and Equities
 $950.00M ▲$670.00M ▼$810.00M ▲$1.02Bn ▲
Investment Management
Investment Management
 $20.00M ▲$20.00M ▲$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue and profits move with the deal-making cycle, but the trend over the last few years shows strong recovery after quieter periods. After an exceptional peak earlier in the decade and a softer stretch, activity and earnings have recently bounced back, with profitability improving again. Margins remain healthy for an advisory firm, though results are inherently volatile and depend heavily on capital markets and M&A conditions.

Balance Sheet

Balance Sheet The balance sheet looks relatively solid for an advisory business. Assets and shareholder equity have grown steadily, cash levels are comfortable, and debt appears manageable rather than aggressive. Overall, the company seems to have a conservative financial foundation, which can help it navigate downturns in deal activity.

Cash Flow

Cash Flow Cash generation from the core business has been consistently strong, even though it rises and falls with the transaction cycle. The firm spends relatively little on physical investments, so most operating cash turns into free cash flow. This gives management flexibility for dividends, buybacks, hiring, and strategic investments when opportunities arise.

Competitive Edge

Competitive Edge Evercore holds a strong position as a leading independent advisory firm, known for high-touch service, senior-level attention, and conflict-free advice. Its brand, track record in major M&A and restructurings, and deep sector expertise create a meaningful moat. The main risks are fierce competition from both large universal banks and other boutiques, heavy reliance on key senior bankers, and exposure to swings in global deal volumes.

Innovation and R&D

Innovation and R&D Innovation is focused on using technology to enhance, not replace, its advisory strengths. The firm is investing in data analytics and artificial intelligence to support deal analysis, partnering with specialized platforms like Mosaic to automate modeling, and upgrading digital tools for wealth clients. These are incremental, practical improvements rather than headline-grabbing breakthroughs, and their impact will depend on effective adoption by bankers and clients.

Summary

Evercore combines a strong franchise in high-end advisory with a sound financial profile and solid cash generation. The business is cyclical and depends on healthy capital markets, but it has shown an ability to rebound when activity returns. Its independence, reputation, and talent base are key strategic assets, while measured technology investments and international expansion aim to support future growth. The main uncertainties lie in the inherent volatility of M&A and capital markets, competition for top bankers, and the broader macro environment.

NEWS

November 28, 2025 · 7:30 AM UTC

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Read more

November 26, 2025 · 8:00 AM UTC

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Read more

November 26, 2025 · 6:45 AM UTC

Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference

Read more

November 25, 2025 · 8:30 AM UTC

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Read more

November 25, 2025 · 8:00 AM UTC

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Read more